Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 6/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.45 |
| ▸ | GHSR | Q92847 | 2/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1784466 | 0.88 | GHSR (0.42) | HCAR1GHSRHCRTR1HCRTR2KDM4E | |
| SCHEMBL1787503 | 0.87 | HCAR1 (0.46) | HCAR1HCAR2GHSRHCRTR1HCRTR2 | |
| SCHEMBL1785903 | 0.84 | MAPT (0.41) | GHSRKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1784772 | 0.84 | HSP90AA1 (0.37) | HCAR1HCAR2GHSRHSP90AA1HSP90B1 | |
| SCHEMBL1784767 | 0.82 | HCAR1 (0.41) | HCAR1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1784464 | 0.81 | ACLY (0.42) | HCAR1KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL25046978 | 0.79 | MAPT (0.45) | KDM4EALDH1A1LMNATHRB | |
| SCHEMBL3706149 | 0.77 | GHSR (0.41) | GHSRTDP1HCRTR1HCRTR2KDM4E | |
| SCHEMBL1785351 | 0.76 | CAPN1 (0.42) | GHSRHCRTR1HCRTR2KDM4EALDH1A1 | |
| SCHEMBL1787561 | 0.75 | BAZ2B (0.42) | HCAR1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2607357-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2013-06-26 | — | — | EP | disclosed |
| US-20120115845-A1 | THERAPEUTIC AGENTS | ALLEN JACK MCQUEEN (GB) | 2012-05-10 | — | — | US | disclosed |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | US | disclosed |
| EP-2205576-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-07-14 | — | — | EP | disclosed |
| US-20090186870-A1 | Therapeutic Agents - 802 | ASTRAZENECA AB (SE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009047558-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203730-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | HCAR1 212/4885HCAR2 301/4885GHSR 2/4885 |
| US-20120115845-A1 | THERAPEUTIC AGENTS | GPR119, MC2R, MC4R | HCAR1 1153/4885HCAR2 1883/4885GHSR 30/4885 |
| US-20090186870-A1 | Therapeutic Agents - 802 | GPR119, SLC5A2, MC2R | HCAR1 961/4885HCAR2 632/4885GHSR 59/4885 |
| US-20110124621-A1 | BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS | GPR119, GHSR, GLP1R | HCAR1 212/4885HCAR2 301/4885GHSR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.